DB16369Investigational
Matrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax. This compound is administered alongside vaccines to enhance biological functions: creating robust and...
- Mechanism
- Curator reviewed · 1 reference
Matrix-M can enhance activated T-cell, B-cell, and antigen-presenting cell populations by inducing the influx of antigen-presenting cells. It can also enhance both B-cell immunity and T-cell immunity.
- Also known as
- Matrix-M1 · Matrix-M1 Adjuvant
- Code names
- Matrix-M
Resolves to
Compound
Clinical / RWD
What you can answer from here — as of September 05, 2026
Which companies are running trials of Matrix-M, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account